BioMarin Hopes A Single Warranty Will Make Gene Therapy Reimbursement Simpler
Firm Is Offering Same Outcomes-Based Deal To All Payers
Executive Summary
The management team talked to Scrip at J.P. Morgan about plans for launching the first gene therapy for hemophilia A in Europe and the US, and its unique approach to reimbursement.
You may also be interested in...
Gene Therapy Reimbursement Remains A Barrier To Commercialization
Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell & Gene Meeting on the Mesa.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
New Gene Therapies Have Hit The Market; Drug Makers Discuss Initial Launch Trends
BioMarin, Sarepta and bluebird bio are all launching new gene therapies in the US. The drug makers updated investors on the commercial execution during second quarter financial earnings calls.